Nature Medicine

Oral small-molecule GLP-1 receptor agonist safiglipron in early type 2 diabetes: a randomized, double-blind, placebo-controlled trial

By Miao Yu, Liang Peng, Chengyan Jiang, Xinhua Xiao

Randomised trial in 284 peopleInterventions

32 weeks

The paper

Miao Yu, Liang Peng, Chengyan Jiang, Xinhua Xiao

Chinese Academy of Medical Sciences & Peking Union Medical College

Nature Medicine, 29 Sep 2026

doi.org/10.1038/s41591-026-04651-9 PubMed 42811187

The New England Journal of Medicine4 Oct 2026
Survodutide reduces weight in adults with diabetes and obesity
Lancet4 Oct 2026
Retatrutide reduces bodyweight in obesity and type 2 diabetes
Lancet4 Oct 2026
Orforglipron matches insulin glargine on cardiovascular safety
Nature Medicine4 Oct 2026
Semaglutide may protect kidneys by reducing vascular resistance